Research Output per year
Fingerprint Dive into the research topics where Huamin Li is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Hereditary Angioedemas
Medicine & Life Sciences
Complement C1 Inhibitor Protein
Medicine & Life Sciences
Angioedema
Medicine & Life Sciences
Placebos
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Safety
Medicine & Life Sciences
Plasma Kallikrein
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 1996 2019
Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study
SAHARA study group, May 1 2019, In : Journal of Allergy and Clinical Immunology: In Practice. 7, 5, p. 1610-1618.e4Research output: Contribution to journal › Article
Open Access
Hereditary Angioedemas
Placebos
Safety
Therapeutics
Hereditary Angioedema Types I and II
Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks
Bernstein, J. A., Li, H., Craig, T. J., Manning, M. E., Lawo, J. P., Machnig, T., Krishnarajah, G. & Fridman, M., Mar 7 2019, In : Allergy, Asthma and Clinical Immunology. 15, 1, 13.Research output: Contribution to journal › Article
Open Access
Hereditary Angioedemas
Placebos
Odds Ratio
Therapeutics
Cross-Over Studies
Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: Additional outcomes and subgroup analysis of a placebo-controlled randomized study
Li, H. H., Zuraw, B., Longhurst, H. J., Cicardi, M., Bork, K., Baker, J., Lumry, W., Bernstein, J., Manning, M., Levy, D., Riedl, M. A., Feuersenger, H., Prusty, S., Pragst, I., Machnig, T. & Craig, T., Aug 28 2019, In : Allergy, Asthma and Clinical Immunology. 15, 1, 49.Research output: Contribution to journal › Article
Open Access
Hereditary Angioedemas
Complement C1 Inhibitor Protein
Placebos
Therapeutics
Hereditary Angioedema Types I and II
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study
Riedl, M. A., Aygören-Pürsün, E., Baker, J., Farkas, H., Anderson, J., Bernstein, J. A., Bouillet, L., Busse, P., Manning, M., Magerl, M., Gompels, M., Huissoon, A. P., Longhurst, H., Lumry, W., Ritchie, B., Shapiro, R., Soteres, D., Banerji, A., Cancian, M., Johnston, D. T. & 17 others, , Sep 1 2018, In : Allergy: European Journal of Allergy and Clinical Immunology. 73, 9, p. 1871-1880 10 p.Research output: Contribution to journal › Article
Hereditary Angioedemas
Kallikreins
Angioedema
Placebos
Plasma Kallikrein
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema
Lumry, W. R., Craig, T., Zuraw, B., Longhurst, H., Baker, J., Li, H., Bernstein, J. A., Anderson, J., Riedl, M. A., Manning, M. E., Keith, P. K., Levy, D. S., Caballero, T., Banerji, A., Gower, R. G., Farkas, H., Lawo, J. P., Pragst, I., Machnig, T. & Watson, D. J., Jan 1 2018, (Accepted/In press) In : Journal of Allergy and Clinical Immunology: In Practice.Research output: Contribution to journal › Article
Hereditary Angioedemas
Quality of Life
Placebos
Anxiety
Efficiency